Results 31 to 40 of about 2,397,304 (343)

NANETS/SNMMI Procedure Standard for Somatostatin Receptor–Based Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE

Journal of Nuclear Medicine, 2019
With the recent approval of 177Lu-DOTATATE for use in gastroenteropancreatic neuroendocrine tumors, access to peptide receptor radionuclide therapy is increasing.
T. Hope, A. Abbott, K. Colucci, D. Bushnell, Linda Gardner, W. S. Graham, Sheila Lindsay, D. Metz, D. Pryma, M. Stabin, J. Strosberg   +10 more
semanticscholar   +1 more source

Peptide receptor radionuclide therapy (PRRT) in radioiodine-refractory thyroid cancer: A case report of significant response to lu177 DOTA-TATE treatment

Archives of Endocrinology and Metabolism, 2022
SUMMARY A 59-year-old woman with follicular thyroid carcinoma underwent total thyroidectomy followed by radioiodine treatment. Following treatment, the whole-body scan did not show any abnormal radioiodine uptake. However, during the follow-up, the serum
Saeideh Ataei-Nakhaei, Kamran Aryana, Sayyed Mostafa Mostafavi, Hadis Mohammadzadeh Kosari, Mohammad Esmatinia, Atena Aghaee   +5 more
doaj   +1 more source

An expression signature of the angiogenic response in gastrointestinal neuroendocrine tumours: correlation with tumour phenotype and survival outcomes. [PDF]

, 2013
BACKGROUND: Gastroenteropancreatic neuroendocrine tumours (GEP-NETs) are heterogeneous with respect to biological behaviour and prognosis. As angiogenesis is a renowned pathogenic hallmark as well as a therapeutic target, we aimed to investigate the ...
A Couvelard, A Giatromanolaki, A Rinke, AM Marion-Audibert, AT Dimou, B Terris, D Hanahan, D J Pinato, D O’Toole, DC Metz, DJ Pinato, DJ Pinato, E Raymond, EP Hui, F Panzuto, G Kloppel, HS Kim, I Albrecht, IM Modlin, J LeCouter, J Strosberg, J Zhang, JC Yao, JT Chi, JY Scoazec, K Hirabayashi, K Meeran, K Villaume, M Dal Monte, M Perigny, M Ruscica, MA Maynard, N Martin, N Ngo, P Kuiper, R Dina, R Katoh, R Mentlein, R Ramachandran, R Sharma, S Ezziddin, S T K Toussi, T M Tan, VD Corleto, Y Arvidsson, Y Seo, Y Takahashi, YC Patel   +47 more
core   +2 more sources

Targeted radiotherapy of neuroblastoma: future directions [PDF]

, 2017
No abstract ...
Gaze, Mark N., Mairs, Robert, Nile, Donna L., Rae, Colin, Tesson, Mathias   +4 more
core   +2 more sources

Biological and Biochemical Basis of the Differential Efficacy of First and Second Generation Somatostatin Receptor Ligands in Neuroendocrine Neoplasms

International Journal of Molecular Sciences, 2019
Endogenous somatostatin shows anti-secretory effects in both physiological and pathological settings, as well as inhibitory activity on cell growth. Since somatostatin is not suitable for clinical practice, researchers developed synthetic somatostatin ...
F. Gatto, F. Barbieri, M. Arvigo, S. Thellung, Jessica Amarù, M. Albertelli, D. Ferone, T. Florio   +7 more
semanticscholar   +1 more source

The somatostatinergic system in the mammalian cochlea

BMC Neuroscience, 2011
Background Little is known about expression and function of the somatostatinergic system in the mammalian cochlea. We have previously shown that somatostatin administration may have a protective effect on gentamicin-induced hair cell loss. In this study,
Kapfhammer Josef P, Brand Yves, Setz Cristian, Hanusek Claudia, Radojevic Vesna, Bodmer Daniel   +5 more
doaj   +1 more source

Pharmacological Characterization of Veldoreotide as a Somatostatin Receptor 4 Agonist

Life, 2021
Veldoreotide, a somatostatin analogue, binds to the somatostatin receptors (SSTR) 2, 4, and 5. The current aim was to assess its pharmacological activity as an SSTR4 agonist.
Pooja Dasgupta, Thomas Gűnther, Stefan Schulz   +2 more
doaj   +1 more source

Dual Somatostatin Receptor/FDG PET/CT Imaging in Metastatic Neuroendocrine Tumours: Proposal for a Novel Grading Scheme with Prognostic Significance

Theranostics, 2017
Background: PET scans using FDG and somatostatin receptor imaging agents have both been used to study neuroendocrine tumours. Most reports have documented the sensitivity and specificity of each radiopharmaceutical independently, and even suggested the ...
D. Chan, N. Pavlakis, G. Schembri, E. Bernard, E. Hsiao, A. Hayes, T. Barnes, C. Diakos, M. Khasraw, J. Samra, E. Eslick, P. Roach, A. Engel, S. Clarke, D. Bailey   +14 more
semanticscholar   +1 more source

Evaluation of somatostatin and nucleolin receptors for therapeutic delivery in non-small cell lung cancer stem cells applying the somatostatin-analog DOTATATE and the nucleolin-targeting aptamer AS1411. [PDF]

PLoS ONE, 2017
Cancer stem cells represent the putative tumor-driving subpopulation thought to account for drug resistance, relapse, and metastatic spread of epithelial and other cancer types.
Sif Holmboe, Pernille Lund Hansen, Helge Thisgaard, Ines Block, Carolin Müller, Niels Langkjær, Poul Flemming Høilund-Carlsen, Birgitte Brinkmann Olsen, Jan Mollenhauer   +8 more
doaj   +1 more source

Pasireotide for the Medical Management of Feline Hypersomatotropism [PDF]

, 2015
BACKGROUND: Feline hypersomatotropism (HST) is a cause of diabetes mellitus in cats. Pasireotide is a novel multireceptor ligand somatostatin analog that improves biochemical control of humans with HST.
Abraham, Adams, Alt, Appleton, Bhayana, Bruns, Castillo, Church, Colao, Colao, Cuevas-Ramos, Fedele, Fernandez-Rodriguez, Fougner, Golor, Henry, Hofland, Juul, Katznelson, Kvols, Lamb, Lamberts, Maxwell, Meij, Miller, Murray, Myers, Niessen, Niessen, Niessen, Niessen, Petrus, Polska, Rand, Ray, Schmid, Schmid, Sheppard, Slingerland, Sohmiya, Starkey, Stolk, Taboada, Wajchenberg, Zatelli, Zou   +45 more
core   +2 more sources